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Binding Sites and T-Cell Responses to
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Claire Jenkinson1, Rosalind E. Jenkins1, Maja Aleksic2, Munir Pirmohamed1, Dean J. Naisbitt1 and
B. Kevin Park1
Exposure to p-phenylenediamine (PPD) is associated with the development of T-cell-mediated allergic contact
dermatitis. The purpose of this study was to define the nature of the interaction of PPD with the protein and the
antigenic determinant that stimulates T cells. Mass spectrometry was employed to show that PPD oxidation
products bind irreversibly to cysteine (Cys, position 34) in human serum albumin (HSA). A modified tryptic
peptide was characterized with an increase in mass of 106Da, corresponding to the addition of PPD and not to
the secondary products of self conjugation. Lymphocytes from 10 PPD-allergic patients, but not tolerant/naive
individuals, were stimulated with PPD and PPD-modified HSA. A total of 70 PPD-specific and 10 PPD–HSA-
specific CD4þ , CD8þ , and CD4þCD8þ , Th2-secreting T-cell clones were generated from three allergic patients.
In total, 40 clones were stimulated with both PPD and PPD-modified HSA. PPD-modified HSA triggered T-cell
responses through a classical hapten mechanism involving processing. Presentation of PPD to several clones
was dependent on protein complex formation (42 out of 48) and processing (32 out of 68); however, 12% of
clones were triggered with PPD directly. These data identify Cys as the single target for PPD–HSA binding, and
show that PPD protein adducts are antigenic determinants in patients with contact dermatitis.
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INTRODUCTION
Chemicals associated with skin sensitization are electrophi-
lic, low molecular weight molecules that form strong
irreversible bonds with self protein to generate immunogenic
hapten–protein complexes (Divkovic et al., 2005). Antigen
(Ag)-specific T cells are thought to be stimulated by major
histocompatibility complex (MHC)-associated peptides de-
rived from the hapten–protein complex after endogenous
processing by Ag-presenting cells. The nature of specific
hapten–protein-binding interactions and the way in which
hapten–protein complexes stimulate immune cells remains
ill-defined. In fact, definitive evidence relating hapten–pro-
tein complex formation to T-cell activation is lacking; it
remains a possibility that haptens bind directly to MHC
molecules or MHC-embedded peptides to stimulate a specific
T-cell response (Pichler, 2003).
The picture is further complicated for chemicals known as
pre (or pro) haptens, which acquire protein reactivity through
auto/metabolic activation (Lepoittevin, 2006); oxidation
processes generate haptenic determinants that may bind
preferentially to different amino acids or to the same amino
acid residue at different positions in the protein structure.
The aim of this study was to use human serum albumin
(HSA) to characterize p-phenylenediamine (PPD)–protein
complex formation, the T-cell stimulatory capacity of PPD-
modified protein, and mechanisms of PPD-specific T-cell
activation. HSA was chosen as a model protein for several
reasons. First, HSA is the most abundant plasma protein;
second, it contains a single cysteine (Cys) in a reduced
form and, therefore, available for hapten complex formation;
and finally, the T-cell stimulatory capacity of hapten–HSA
complexes has been shown previously (Brander et al., 1995).
p-Phenylenediamine is one of the most frequently
encountered sensitizers owing to its wide use as an
intermediate in permanent hair dye formulations (Corbett
et al., 1973), in printing ink and photo development (Shapiro
et al., 2001), and more recently in henna tattoos (Matulich
and Sullivan, 2005). The increasing incidence of allergic
reactions to PPD has been shown to be related to the
widespread use of consumer products (McFadden et al.,
2007).
p-Phenylenediamine itself is not directly protein reactive.
However, auto-oxidization on skin and in aqueous solution
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generates an electrophilic quinonediimine intermediate that
is susceptible to subsequent sequential oxido-conjugation
reactions. The product of these reactions is Bandrowski’s
base (BB), a derivative of three conjugated PPD molecules
(Picardo et al., 1990; Coulter et al., 2007; Aeby et al., 2009).
Through this same oxidative chemistry, PPD can bind
irreversibly to protein (Coulter et al., 2007, 2008), generating
potential hapten–protein complexes. The reaction profile of
the PPD-related compound 2,5-dimethyl-p-benzoquinone-
diimine with single nucleophilic amino acids has been
studied in detail (Eilstein et al., 2006, 2007). It binds directly
to Cys, and other amino acids, through a series of complex
chemical pathways. The selectivity of the compound toward
lysine residues in a model peptide containing potentially
reactive amino acids (except Cys) suggests that lysine might
also be an important amino acid for hapten complex
formation (Eilstein et al., 2008).
p-Phenylenediamine and BB are classed as potent skin
sensitizers in the mouse (Warbrick et al., 1999; White et al.,
2006). In these model systems, the immunostimulatory effects
of PPD are thought to be dependent on cutaneous oxidation
and generation of BB (Aeby et al., 2009; Farrell et al., 2009).
Patch testing studies on humans and in vitro analysis of
lymphocyte proliferation suggest that the nature of the
antigenic determinant is different in allergic patients. Patch
testing using PPD, which has a high positive predictive value
(Ho et al., 2005), is time-dependent (Basketter et al., 2006)
indicating that oxidation might be important for immune
reactivity. Only 16% of PPD patch test-positive patients are
responsive to BB (White et al., 2006); thus, primary oxidation
products of PPD are thought to be major antigenic
determinants. Looking at the repertoire of Ag-specific T cells
in human subjects, BB stimulates a response in allergic
patients and tolerant individuals, which is apparently not
converted into an allergic reaction (Coulter et al., 2008).
T-cell responses to PPD, which are highly diagnostic, are
restricted to allergic patients (Sieben et al., 2002; Coulter
et al., 2008; Skazik et al., 2008). Herein, we show that
the predominant T-cell response in PPD-allergic patients is
directed against PPD hapten–protein complexes. PPD bound
to HSA at Cys34 represents a distinct antigenic determinant
for certain T-cell clones.
RESULTS
PPD binds irreversibly to HSA
Gel electrophoresis followed by band excision and scintilla-
tion counting for incorporated radioactivity established
that [14C]PPD binds irreversibly to HSA (Figure 1a). Radio-
activity was not associated with non-HSA-containing
bands (Figure 1b). [14C]PPD binding was detectable after
2 hours and increased steadily over a 72-hour period
(Figure 1c).
Selective PPD modification of HSA at Cys 34
Sequence coverage of HSA was 91.3%. PPD modification of
the Cys34-containing peptide 21–41 (ALVLIAFAQYLQQCP-
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Figure 1. Irreversible binding of p-phenylenediamine (PPD) to human serum albumin (HSA). (a) [14C]PPD-treated HSA separated by electrophoresis on
SDS-polyacrylamide gels under reducing conditions. (b) Bands were excised and the incorporated [14C]PPD determined by scintillation counting. (c) Time-
dependent binding of [14C]PPD to HSA was measured by scintillation counting. (d) Liquid chromatography-mass spectrometry (MS)/MS sequence analysis
of HSA peptide, ALVLIAFAQYLQQCPFEDHVK, MR 2,538.6; 3þ , m/z 847.2. (Unmodified peptide 2,432.6; 3þ , m/z¼ 811.8; 106 a). Cysteine 34 (Cys34)
shows PPD modification.
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FEDHVK) was observed; the peptide mass increased
from 2,432.6 (3þ , m/z 811.8) to 2,538.6 (3þ , m/z 847.2),
corresponding to an increase of 106 AMU. Fragmentation of
m/z 847.2 ion revealed the y8 fragment ion at m/z 1,080,
corresponding to Cys34 plus 106 AMU, confirming a direct Cys
modification (Figure 1d). No modification of lysine residues,
as detected by Eilstein et al. (2008), was detected.
PPD did not dissociate from the PPD-modified HSA
complex. Unbound PPD was not detected in conjugate-
containing supernatants cultured for up to 130 hours (data not
shown).
PPD and PPD-modified HSA stimulate lymphocytes in allergic
patients
Lymphocytes from allergic patients were found to proliferate
after in vitro stimulation with PPD and PPD-modified
HSA (Table 1). Low PPD concentrations (0.1–10 mgml1)
stimulated a T-cell response, whereas higher concentrations
inhibited lymphocyte proliferation, a phenomenon asso-
ciated with the previously described in vitro toxicity of PPD
(Coulter et al., 2007) (Figure 2). Significantly higher
concentrations of PPD-modified HSA (250–2,000mgml1)
were required to stimulate a proliferative response (Figure 2).
However, direct comparison of the strength of the induced
proliferative response with equivalent PPD concen-
trations associated with HSA and soluble PPD (Figure 2b),
and calculated based on mass spectrometry experi-
ments showing that one mole of PPD binds per mole
of HSA, revealed that irreversibly bound PPD represents
a more potent antigenic signal. Importantly, unbound
PPD was not detected by radiometric HPLC, mass spectro-
metry, or scintillation counting in experiments containing
PPD-modified HSA, indicating that the observed res-
ponse of lymphocytes was not due to PPD itself. Untreated
HSA (up to 2mgml1) did not stimulate lymphocyte
proliferation.
Table 1. Clinical details from PPD-allergic patients and tolerant individuals
Months since
LTT (SI)
Age (years) Sex Dye use PPD allergy Other allergies reaction Patch test PPD PPD–HSA
Allergic patients
1 37 F Yes Yes Nickel, cobalt, nail polish, pollen, latex, benzoic acid,
and benzyl peroxide
252 + 2.3 2.5
2 43 F Yes — — 17 + 10.7 76.2
3 77 F Yes Yes — 18 + 11.02 20.2
4 51 F Yes Yes Hay fever 24 + 3.3 2.4
5 33 F Yes Yes Nickel, colorings, and preservatives 22 + 12.2 18.9
6 68 F Yes Yes Nickel, copper, latex 44 + 5.5 51.2
7 52 F Yes Yes E45 cream, orange coloring, and biological soap 14 + 12.3 54.9
8 70 F Yes Yes Penicillin, make up, creams, nickel, leather, tea tree oil,
and fragrances
11 + 17.8 2.2
9 56 F Yes Yes Nickel and perfumes 22 + 15.3 38.2
10 43 F Yes Yes Local anesthetics, nickel, sunglasses, and clothes dye 96 + 34.9 33.5
Volunteers
11 26 F Yes No na np —1 —
12 28 M No No na np — —
13 24 F Yes No na np — —
14 24 F Yes No na np — —
15 24 F Yes No na np — —
16 28 F Yes No na np — —
17 37 M No No na np — —
18 23 F Yes No na np — —
19 27 M No No na np — —
20 27 M No No na np — —
F, female; HSA, human serum albumin; LTT, lymphocyte transformation test; M, male; na, not applicable; np, not performed; PPD, p-phenylenediamine;
SI, stimulation index.
1SI o2.
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Lymphocytes from tolerant individuals were not specifi-
cally stimulated with PPD or PPD-modified HSA (stimulation
index (SI) consistently o2) (Figure 2).
Characterization of Ag-specific CD4þ , CD8þ , and
CD4þCD8þ T-cell clones obtained from PPD-allergic patients
After serial dilution of PPD-stimulated lymphocytes from
three allergic patients and clonal expansion, 70 Ag-specific
T-cell clones were identified by measurement of prolifera-
tion. A total of 10 further T-cell clones were detected from
lymphocytes initially stimulated with PPD-modified HSA
(Table 2). Clones displayed a remarkable heterogeneity in CD
marker expression; CD4þ and CD8þ clones were character-
ized from blood of all three allergic patients, whereas dual-
positive clones expressing relatively high levels of CD4þ and
CD8þ were found in two patients.
Ag-stimulated CD8þ and CD4þCD8þ T-cell clones display
cytotoxic activity
Cytotoxic activity of 4 CD4þ , 8 CD8þ , and 11 CD4þCD8þ
T-cell clones was assessed by measuring cell surface
expression of CD107a after Ag stimulation (20 of the clones
were stimulated with PPD, 3 were stimulated with PPD-
modified HSA). Two CD8þ (12.2- and 3.3-fold increase with
PPD) and seven CD4þCD8þ (11.7±9.2 average fold
increase with PPD) clones exhibited greater than a twofold
increase in the expression of the CD107a after incubation
with PPD. Increased CD107a expression was not observed on
PPD-stimulated CD4þ T-cell clones.
Ag-stimulated T-cell clones secrete high levels of Th2 cytokines
When culture supernatants from incubations containing
T cells, Ag-presenting cells, and PPD or PPD-modified HSA
were analyzed for cytokine expression, high levels of the Th2
cytokines, IL-4, IL-5, and IL-13, were detected (Table 3) Ag
stimulation of certain clones was also associated with
secretion of the cytokines IFN-g and IL-8.
Stimulation of T-cell clones with PPD and PPD-modified HSA
Proliferation of T-cell clones with PPD was concen-
tration-dependent; maximal responses were observed with
0.5–2 mgml1 PPD and 500–2,000mgml1 PPD-modified
HSA. The majority of PPD-specific T-cell clones (40 out
of 73) generated from three allergic patients were addi-
tionally stimulated with PPD-modified HSA (Supplementary
Table S1).
PPD stimulates T-cell clones through three pathways
p-Phenylenediamine stimulated T-cell proliferation through
both processing dependent and independent pathways
(Figure 3). Of all the T-cell clones tested from the three
patients, 47% (n¼68) were stimulated when PPD was
presented in the context of glutaraldehyde-fixed Ag-present-
ing cells. PPD-modified HSA-specific T-cell proliferation was
inhibited by Ag-presenting cell fixation. To confirm these
fixation data, the kinetics of T-cell receptor internalization
after PPD stimulation was monitored by flow cytometry. For
clones stimulated with PPD through a pathway dependent on
processing, receptor internalization was observed after
4–16 hours. In contrast, receptor internalization was observed
rapidly (within 1 hour) for clones stimulated with PPD
directly, in the absence of processing (Figure 3).
T-cell clones stimulated with PPD through a processing-
dependent pathway were also stimulated with PPD-pulsed
Ag-presenting cells, signifying a requirement for hapten
complex formation. T-cell clones responding to PPD in the
absence of processing were predominantly stimulated with
PPD bound irreversibly to protein, presumably MHC itself, or
a peptide embedded within (Figure 4). Only six clones
responding to soluble PPD did not show specific proliferation
with PPD-pulsed Ag-presenting cells. T-cell responses were
also demonstrable when Ag-presenting cells were pulsed
with PPD-modified HSA (results not shown).
DISCUSSION
Allergic contact dermatitis, a delayed-type, cell-mediated
immune reaction, occurs in response to several electrophilic
low molecular weight molecules. PPD, a chemical found
in many consumer products and associated with a high
incidence of allergic reactions (McFadden et al., 2007), is
able to induce dendritic cell co-stimulatory signaling (Hulette
et al., 2005; Coulter et al., 2007; Aeby et al., 2009) and
provide the antigenic signals (Krasteva et al., 1993; Sieben
et al., 2002; Coulter et al., 2008) required to stimulate T-cell
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Figure 2. Stimulation of lymphocyte proliferation with p-phenylenediamine
and p-phenylenediamine-modified human serum albumin. (a) p-phenylene-
diamine (PPD) and PPD-modified human serum albumin (HSA) stimulate
proliferation of lymphocytes from allergic patients (n¼ 10), but not from
tolerant individuals (n¼10). Proliferation was determined by incorporation
of [3H]thymidine. Statistical analysis compares incubations in the
presence and absence of antigen (*Po0.05). (b) Lymphocyte proliferation
with PPD and PPD-modified HSA with a curve superimposed to represent
the estimated concentration of PPD associated with HSA at each
concentration tested (c) Maximum proliferation of the lymphocytes of
allergic patients and tolerant individuals stimulated with PPD and
PPD-modified HSA.
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responses. Despite this, the nature of the interaction of PPD
with immune cells remains ill-defined. The focus of the
present study was to characterize PPD hapten–protein
complex formation using mass spectrometric methods and
explore mechanisms of PPD T-cell presentation.
Previously, T-cell responses to the PPD oxidation product
BB have been detected in lymphocytes from allergic patients
and tolerant individuals; however, T-cell stimulation with
PPD itself is discernable with lymphocytes from allergic
patients alone (Sieben et al., 2002; Coulter et al., 2008;
Skazik et al., 2008). Thus, detection of PPD-specific T-cell
responses represents an important discrimination between
allergic and tolerant patient groups, and is the reason why the
current study focuses on characterization of T-cell responses
to PPD and primary products of auto-oxidation, but not
synthetic BB.
Hapten–protein complex formation is thought to be an
important primary step in the development of allergic
contact dermatitis. Since the definitive studies of Landsteiner
and Jacobs (1935), reactivity of chemical allergens toward
nucleophilic amino acid residues on protein has been
coupled with sensitization potential (Basketter et al., 1997).
This resulted in the hypothesis that binding of chemical
allergens to specific loci on protein might be associated
with activation of immune cells. The strong sensitizer 2,
4-dinitrochlorobenzene binds to a large number of cellular
proteins (Pickard et al., 2007); however, studies with
isolated proteins have identified a degree of selectivity of
nucleophilic amino acid modification residing in specific
microenvironments of the protein structure (Aleksic et al.,
2007, 2008).
2,5-Dimethyl-p-benzoquinonediimine, a derivative of
PPD p-benzoquinonediimine, has been shown to bind
irreversibly to several nucleophilic amino acid residues
(Eilstein et al., 2006, 2007, 2008). In the present study,
PPD bound to the single Cys residue on HSA existing in a
reduced form (Cys-34) (Figure 1). Cys-34 interacts with the
hydroxyl oxygen of Tyr84 by hydrogen bonding in unmodi-
fied HSA (Stewart et al., 2005). PPD ligation will disrupt this
hydrogen bonding interaction, inducing a conformational
change that alters functional activity (Kawakami et al., 2006)
and possibly generating new antigenic determinants.
Table 2. Proliferation and CD phenotype of T-cell clones generated from three allergic patients
Proliferation (c.p.m.)
CD phenotype PPD-specific (n) 0 PPD Activity with PPD–HSA
PPD stimulation
1 CD4þ 21 599.3 2,438.6 19%1 (16)
CD8þ 9 1,344.8 8,365.7 50% (8)
CD4þCD8þ 0 — — —
2 CD4þ 2 239.3 6,609.5 50% (2)
CD8þ 4 207 6,711.4 0% (3)
CD4þCD8þ 11 2,371.1 16,047.4 64% (11)
3 CD4þ 20 427.3 6,585.3 70% (20)
CD8þ 2 1,134.8 19,118.3 50% (2)
CD4þCD8þ 1 2,40.5 4,286.5 0% (1)
Proliferation (c.p.m.)
CD phenotype PPD–HSA-specific (n) 0 PPD–HSA Activity with PPD
PPD-modified HSA stimulation
1 CD4þ 0 — — —
CD8þ 0 — — —
CD4þCD8þ 0 — — —
2 CD4þ 2 251.3 643 100% (2)
CD8þ 3 269.8 1,529.7 100% (3)
CD4þCD8þ 0 — — —
3 CD4þ 5 550.7 2826.3 100% (5)
CD8þ 0 — — —
CD4þCD8þ 0 — — —
c.p.m., counts per minute; HSA, human serum albumin; PPD, p-phenylenediamine.
1% of T-cell clones with additional antigen specificity (n).
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p-Phenylenediamine modification of HSA at Cys-34 was
characterized by the addition of 106 AMU on the relevant
tryptic peptide, corresponding to the addition of a single
molecule of PPD and not secondary oxidation products,
including BB. As illustrated by Eilstein et al. (2006), the
reaction likely proceeds through a classical nucleophilic
mechanism. Unlike previous studies exploring reaction
profiles with isolated nucleophilic amino acids and small
peptides, excluding Cys, hapten–protein complex formation
with other amino acid residues (for example, lysine and
tryptophan) was not detected. These findings imply that
covalent modification of Cys residues predominate over
alternative conjugating pathways in protein; hence, the
antigenic potential of PPD and PPD-modified HSA with
lymphocytes and T-cell clones from allergic patients has been
investigated.
In initial experiments, the lymphocyte transformation test,
which is a sensitive and specific assay to diagnose drug
allergy and contact sensitization (Sieben et al., 2002; Naisbitt
et al., 2003b; Pichler and Tilch, 2004; Wu et al., 2006;
Pickard et al., 2007), was used to explore lymphocyte
stimulation with PPD and PPD-modified HSA. In agreement
with previous work (Sieben et al., 2002; Coulter et al., 2008),
lymphocytes from 10 allergic patients were stimulated to
proliferate in response to low concentrations of PPD; higher
concentrations inhibited proliferation because of the direct
toxicity of PPD in culture (Figure 2). These data clearly
indicate that PPD-related antigenic signals associated with
lymphocyte proliferation are observed at low concentrations
that do not stress cells or mediate co-stimulatory signaling
(Coulter et al., 2007). The strength of the proliferative
response observed (SI greater than 10 in 7/10 patients)
compares favorably with most drug and chemical Ags
(Nyfeler and Pichler, 1997; Pichler and Tilch, 2004), which
indicates that exposure of lymphocytes to PPD directly
represents an important antigenic determinant in many
patients. Patient lymphocytes were also stimulated to
proliferate vigorously with PPD-modified HSA. Higher
concentrations of PPD-modified HSA were required to trigger
a proliferative response; however, comparison of the strength
of the induced response with equivalent soluble and
conjugated PPD concentrations revealed that conjugated
PPD represents a more potent antigenic signal (Figure 2b). Of
particular importance to our discussion was an absence of
detectable free PPD in PPD-modified HSA cultures that might
be immunostimulatory; analyses performed included radio-
metric HPLC, liquid chromatography-mass spectrometry
(MS), and scintillation counting. Interestingly, the response
of lymphocytes from patients (for example, patients 6 and 8)
differed in terms of their preferred antigenic determinant (that
is, PPD or PPD-modified HSA; Table 1); possibly highlighting
alternative preferred pathways of Ag presentation.
To explore mechanisms of PPD presentation to specific
T-cell receptors and the extent of cross-reactivity between
soluble and conjugated PPD, T cells were cloned. The
occurrence of CD4þ , CD8þ , and CD4þCD8þ T-cell clones
Table 3. Cytokine secretion from PPD-specific T-cell clones generated from three allergic patients
Cytokine secretion (pgml1)
Clone no CD Proliferation (SI) IL1a IL4 IL5 IL6 IL8 IL9 IL10 IL13 TNFa IFNc
PPD stimulation
16 Dual 283 01 10000 7287 16 1391 2 8 8830 6 1361
26 Dual 38 1 2060 1539 32 60 0 10 7205 0 179
34 4 8 0 384 654 34 25 0 0 8268 29 57
44 Dual 8 1 20 21 0 0 0 0 660 22 11
23 Dual 46 2 4472 2299 36 138 0 0 9238 25 324
29 4 74 0 1993 1419 36 58 0 10 7064 8 87
15 4 15 1 1969 7765 16 113 0 3 12427 3 400
21 4 8 2 44 1785 14 55 0 6 9199 17 65
39 4 50 0 123 4614 7 0 0 18 9792 0 78
49 4 26 12 92 181 9 0 0 2 2812 0 43
64 8 46 6 44 3022 17 0 0 0 9392 18 56
65 Dual 17 0 0 121 0 6 0 5 1782 0 45
PPD-modified HSA stimulation
33 4 3 0 1 169 0 0 0 2 1246 0 11
40 4 2 0 28 233 17 199 0 8 2334 0 22
172 8 8 0 17 0 0 0 0 0 0 8 3
HSA, human serum albumin; PPD, p-phenylenediamine; SI, stimulation index; TNF, tumor necrosis factor.
1Values correspond to cytokine secretion with control (unstimulated) levels subtracted.
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varied between the allergic patients, even though each
patient presented with similar clinical symptoms (Table 2).
These findings did not relate to variation in sample collection,
methods employed, or materials used, as these are all
standardized in the authors’ laboratory. Previous studies
using lymphocytes from PPD-allergic patients (Sieben et al.,
2002; Coulter et al., 2008), showed that Ag-stimulated T cells
secrete high levels of the Th2 cytokines, IL-4, IL-5, and IL-13.
Data presented in the current study show that the cytokine
secretion profile of allergic patient T cells did not differ when
CD4þ , CD8þ , and CD4þCD8þ T-cell clones were com-
pared or when PPD and PPD-modified HSA were used as Ags
(Table 3).
Murine models of contact dermatitis suggest that CD8þ
cells are effectors mediating cytotoxicity through FAS and
perforin pathways (Kehren et al., 1999; Martin et al., 2004;
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Figure 3. Mechanism(s) of antigen presentation to p-phenylenediamine-specific T-cell clones. T-cell clones are stimulated with (a) p-phenylenediamine (PPD)
through processing and independent pathways, and with (b) PPD-modified human serum albumin (HSA) through a pathway dependent on processing.
T-cell clones were incubated with PPD and irradiated or glutaraldehyde-fixed antigen-presenting cells. Proliferation was determined by incorporation of
[3H]thymidine. Coefficient of variation was consistentlyo20%. Charts show representative clones and tables illustrate the number of clones with that particular
profile. (c) Time-dependent internalization of T-cell receptor expression on PPD-specific T-cell clones.
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clones were incubated with soluble PPD and antigen-presenting cells pulsed with PPD for 16 hours. Proliferation was determined by incorporation of
[3H]thymidine. Coefficient of variation was consistently o20%. Charts show representative clones and tables illustrate the number of clones in that particular
profile.
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Saint-Mezard et al., 2005; Vocanson et al., 2006, 2009).
Although a detailed investigation of the involvement of
different T-cell populations in PPD-mediated contact derma-
titis was beyond the scope of the current study, Ag-specific
CD8þ and CD4þCD8þ , but not CD4þ , T-cell clones were
found to display a transient increase in cell surface CD107a
expression. CD107a is a membrane-associated protein that
is transported to the cell surface during degranulation.
Increased CD107a expression after Ag exposure has recently
been described as a sensitive marker of cytotoxic activity
(Betts et al., 2003; Aktas et al., 2009).
Previous studies using cloned T cells propose that specific
T-cell receptors are predominantly stimulated with PPD
bound directly to MHC molecules, therefore circumventing
the requirement for Ag processing (Sieben et al., 2002).
Importantly, Ag-presenting cells cultured with PPD for up to
4 hours failed to stimulate a specific T-cell response (Sieben
et al., 2002). In contrast, more recent studies indicate that a
longer 16–24-hour pulse of Ag-presenting cells with PPD, the
time needed for oxidation of PPD and covalent binding
(Coulter et al., 2007; Aeby et al., 2009), is associated with a
PPD-specific proliferative response (Coulter et al., 2008).
Thus, PPD–protein complex formation seems to represent an
additional antigenic signal to T cells from allergic patients. Of
the 63 PPD-specific clones that were tested for additional
reactivity with PPD-modified HSA, a proliferative response
was detected with 31 clones (Table 2). All 10 T-cell clones
initially deemed reactive toward PPD-modified HSA, dis-
played additional PPD reactivity. To delineate mechanisms of
Ag presentation to specific T cells, clones were stimulated
with (1) glutaraldehyde-fixed or irradiated Ag-presenting
cells—fixation prevents processing (Zanni et al., 1998;
Schnyder et al., 2000; Wu et al., 2006); and (2) Ag-presenting
cells pulsed overnight with PPD and PPD-modified HSA—
pulsing prevents presentation of weakly bound Ags to T cells.
Stimulation of approximately 90% of T-cell clones
incubated with PPD was dependent on irreversible hapten–-
protein complex formation (Figure 4). PPD oxidation
products were able to stimulate specific T-cell receptors by
binding irreversibly to both MHC-associated and, presum-
ably, non-MHC-associated protein through processing in-
dependent and dependent pathways, respectively. As
described previously (Sieben et al., 2002), T cells were also
stimulated with PPD bound reversibly to MHC though non-
covalent interactions; however, this form of T-cell stimulation
seems to be less-favored, as it was only detected with low
numbers of clones (6 out of 48).
Presentation of PPD-modified HSA to T-cell clones was
dependent on processing, providing unequivocal evidence
that hapten–protein complexes represent an antigenic deter-
minant for T cells from allergic patients. Binding of PPD to
Cys residues in HSA and other proteins, including the
cytosolic protein glutathione-S-transferase Pi (unpublished
data), indicate that numerous haptenic structures are likely to
be formed in exposed patients when PPD is applied to skin at
high concentrations. Liberation of multiple peptide epitopes
through processing would stimulate a promiscuous T-cell
response, explaining why, unlike other inflammatory condi-
tions and certain drug hypersensitivity reactions, strong
associations between particular human leukocyte Ags and
contact allergic dermatitis are not apparent. These data
showing heterogeneous T-cell responses to different Ags have
important ramifications for the interpretation of patch test
responses and the development of new in vitro tests to
diagnose allergic contact dermatitis.
In conclusion, we have shown that PPD selectively
modifies Cys-34 on HSA and this PPD hapten–protein
complex stimulates T cells from allergic patients. In on-going
experiments, we are isolating T cells from patch test-positive
skin biopsy samples to explore the nature of the Ag-
stimulating skin-infiltrating T cells and the involvement of
different homing receptors in cutaneous T-cell infiltration.
MATERIALS AND METHODS
Donor characteristics
Peripheral blood mononuclear cells were isolated from venous blood
obtained from 10 PPD-allergic patients and 10 healthy volunteers
(both PPD tolerant and naive). Allergic patients were selected on the
basis of a clinical diagnosis of PPD-mediated contact dermatitis and a
positive PPD patch test. The volunteer cohort was significantly younger
than the patient cohort; however, our previous study has shown that
Ag specificity is not a function of donor age (Coulter et al., 2008).
Approval for the study was obtained from Liverpool local research
ethics committee; informed written consent was obtained from all
donors. Experiments were conducted in accordance with the
Declaration of Helsinki Principles. Clinical characteristics of the
allergic patients and volunteers are shown in Table 1.
Culture medium for lymphocyte culture and T-cell cloning
Culture medium consisted of RPMI-1640 supplemented with pooled
heat-inactivated human AB serum (10%, v/v), HEPES (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid; 25mM), L-glutamine
(2mM), transferrin (25 mgml1), streptomycin (100 mgml1), and
penicillin (100Uml1). T-cell lines and clones were maintained in
culture medium supplemented with IL-2 (25Uml1).
Cell lines
Epstein-Barr virus-transformed B-cell lines (referred to as Ag-
presenting cells) were generated from peripheral blood lymphocytes
of allergic patients using supernatant from the Epstein-Barr virus-
producing cell line B9-58, according to the established methods
(Wu et al., 2007).
p-Phenylenediamine was obtained from Sigma Chemical (Poole,
Dorest, UK). [14C]PPD (specific activity 60mCimmol1) was
synthesized by GE Healthcare (Bucks, UK). Stock solutions
(10mgml1) were prepared in culture media and DMSO (4:1 v/v),
and diluted as required.
PPD–HSA complex formation
[14C]PPD (150 mM (0.2 mCi)) was incubated with HSA (1mgml1; in
HBSS (Hank’s buffered salt solution), pH 7.4; total volume 6ml) for
0–130 hours to permit hapten–protein complex formation. After 0, 4,
24, 48, 72, and 130hours, the reaction was terminated and protein
extracted by exhaustive solvent extraction with acetonitrile (4
1ml). HSA conjugates were dissolved in NaOH (0.2 M; 1ml).
Aliquots (100ml) were taken from each precipitation step for
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quantification of hapten–protein complex formation and protein
estimation. The time-dependency of [14C]PPD–HSA complex forma-
tion was explored directly by scintillation counting.
To show that PPD binds irreversibly to HSA, an aliquot of protein
was taken after 24 hours and the unbound PPD was removed by
exhaustive solvent extraction, and the protein was precipitated by
the addition of acetonitrile (100 ml). An aliquot containing 20 mg of
total protein was separated by electrophoresis on SDS-polyacryla-
mide gels under reducing conditions. Bands were then excised and
digested. The level of [14C]PPD incorporated into each band was
then determined by scintillation counting.
Specific amino acid modification of HSA by PPD was determined
by incubating HSA (15 mM) with PPD (150 mM; 100ml) for 16 hours in
phosphate buffer at 37 1C. Solvent-extracted samples were reduced
with dithiothreitol (100mM), alkylated with iodoacetamide (55mM),
and solvent washed with methanol (10:1), to remove unbound
material, and suspended in 50mM ammonium bicarbonate. Samples
(100mg) were digested with modified trypsin (5 ng; in 50mM
ammonium bicarbonate) for 16 hours at 37 1C and desalted using
C18 ZipTip columns according to the manufacturer’s instructions
(Millipore, Watford, Hertfordshire, UK). The resultant peptide
mixture was reconstituted in acetonitrile/trifluoroacetic acid (5 ml;
5:0.1%). For liquid chromatography-MS/MS analysis, aliquots of
sample (1 ml) were delivered into a QSTAR Pulsar i hybrid mass
spectrometer (Applied Biosystems; Warrington, UK) by automated
in-line liquid chromatography (integrated LCPackings System, 5mm
C18 nano-precolumn and 75 mm 15 cm C18 PepMap column
(Dionex, Sunnyvale, CA)) through a nano-electrospray source head
and 10mm inner diameter PicoTip (New Objective, Woburn, MA). A
gradient from 5% acetonitrile/0.05% trifluoroacetic acid (v/v) to 48%
acetonitrile/0.05% trifluoroacetic acid (v/v) in 60minutes was
applied at a flow rate of 300 nlmin1, and MS and MS/MS spectra
were acquired automatically in positive ion mode using information-
dependent acquisition (Analyst, Applied Biosystems). Database
searching was performed using ProteinPilot version 1 (Applied
Biosystems) against the latest version of the SwissProt database, with
the confidence level set at 90%. PPD and carboxamidomethyl were
set as a high- and medium-probability user-defined modifications on
specific amino acids, that is, Cys.
Determination of PPD-modified HSA stability
To assess the stability of the PPD-modified HSA complex, [14C]PPD
(150mM (0.2 mCi)) was incubated with HSA (1mgml1; in HBSS, pH
7.4; total volume 6ml) for 16 hours. The reaction was then
terminated and the protein was subjected to exhaustive solvent
extraction with acetonitrile (4 1ml) and reconstituted in 1ml
media. The PPD-modified HSA solution was incubated at 37 1C for
130 hours, the duration of the proliferation assay. After 0, 4, 24, 48,
72, and 130hours, an aliquot of the supernatant was collected and
analyzed by scintillation counting, radiometric HPLC, and liquid
chromatography-MS for the presence of dissociated PPD using
previously described protocols (Coulter et al., 2007).
Determination of lymphocyte proliferation
Proliferation of patient and volunteer lymphocytes with PPD and
PPD-modified HSA (0.1–1,000mgml1) was quantified by measure-
ment of [3H]thymidine, as described previously (Pichler and Tilch,
2004). PPD concentrations of 50 mgml1 and above, which are
associated with significant cell toxicity (Coulter et al., 2007), were
used as a direct comparison with PPD-modified HSA-specific
responses. Proliferative responses were calculated as SI (c.p.m. in
Ag-treated cultures/c.p.m. in cultures with solvent alone). An SI of
greater than or equal to 2 was considered significant.
Generation and characterization of PPD and PPD–protein
complex-specific T-cell clones
For generation of T-cell lines, lymphocytes (1 106; total volume
1ml) isolated from the blood of three allergic patients were
incubated with PPD (2mgml1) or PPD-modified HSA (1mgml1).
The patients were selected on the basis of a positive lymphocyte
transformation test and their willingness to donate repeated
blood samples. IL-2 was added on days 6 and 9 to maintain
Ag-specific proliferation. After 14 days, T-cell lines were cloned
by serial dilution using established methodology (Schnyder et al.,
2000; Naisbitt et al., 2003a; Wu et al., 2006). Briefly, cells
were plated at 0.3, 1, 3 T cells per well and restimulated with
irradiated (60Gy) lymphocytes (0.5 104 per well), IL-2 (60Uml1),
and phytohemagglutinin (1mgml1). IL-2 was added on alternate
days to maintain Ag-specific proliferation until the clones were
ready to test for specificity after 28 days. Purification of T cells
was not required for the generation of CD4þ and CD8þ T-cell
clones.
To test the specificity of the clones, T cells (0.5 105; total
volume 0.2ml) were incubated with irradiated (60Gy) autologous-
transformed B cells (0.1 105) as Ag-presenting cells and the
compound that the lymphocytes were initially stimulated with, that
is, PPD (1–2mgml1) or PPD-modified HSA (0.1–1mgml1). After
48 hours, [3H]thymidine was added and proliferation determined by
scintillation counting. Cell cultures with an SI of greater than or
equal to 2 were expanded further. Autologous Epstein-Barr virus-
transformed B cells were used as a Ag-presenting cells, as they are
available in large numbers and they have previously been shown to
present protein-reactive and non-reactive chemical Ags to T cells
(Schnyder et al., 2000).
Ag-specific T-cell clones were characterized in terms of CD
phenotype by flow cytometry using fluorescent-labelled anti-CD4þ
and anti-CD8þ antibodies (Serotec, Oxford, UK).
Determination of the functionality of PPD and PPD–protein
complex-specific T-cell clones
The concentration of PPD and PPD-modified HSA required to
stimulate proliferation of individual clones was determined by
incubating T cells (0.5 105; total volume 0.2ml) with Ag-
presenting cells (0.1 105) and titrated Ag (PPD, 0.1–5 mgml1;
PPD-modified HSA, 0.1–1 mgml1). Ag-specific proliferative re-
sponses were measured by [3H]thymidine incorporation. Cytokine
secretion (IL-1a, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-13, TNFa,
and IFNg) was measured using a Liquichip 100 workstation
(Qiagen, West Sussex, UK) with LiquiChip IS 2.3 software. Cytotoxic
potential was determined by measuring cell surface expression of
CD107a, a molecule transported to the cell surface by T-cell
receptors during degranulation (Betts et al., 2003; Mittendorf et al.,
2005). T-cell clones (0.5 105; total volume 0.2ml) were incubated
with Ag-presenting cells (0.25 105) in the presence and absence of
PPD (2 mgml1) or PPD-modified HSA (1mgml1). After 2
and 16 hours, cells were harvested, washed, and stained for
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30minutes at 4 1C with a FITC-labelled CD107a mAB (Serotec) and
analyzed by flow cytometry (Coulter Epics, XL software; Beckman
Coulter, Luton, UK).
Determination of the mechanism of Ag presentation to PPD and
PPD–protein complex-specific T-cell clones
The involvement of irreversible protein binding and processing in the
presentation of PPD and PPD-modified HSA to specific T cells was
studied by modifying the standard assay for assessment of T cell
proliferation assay as follows. First, Ag-presenting cells were pulsed
with PPD (2mgml1) or PPD-modified HSA (1mgml1) for 16 hours,
the optimal time for PPD oxidation and protein complex formation
(Coulter et al., 2007, 2008; Aeby et al., 2009). Pulsed Ag-presenting
cells were washed repeatedly, suspended in PPD-free medium, and
added to the proliferation assay in the absence of soluble Ag.
Second, Ag-presenting cells (2 106; 0.5ml) were fixed chemically
with glutaraldehyde (2%; 12.5ml), a procedure that prevents
processing, but not the presentation of pre-processed Ags to T cells
(Zanni et al., 1998; Schnyder et al., 2000; Wu et al., 2006). Third,
the kinetics of T-cell receptor internalization, an early marker of Ag
T-cell receptor engagement, was measured after 1, 4, and 16 hours
using a FITC-labelled anti-CD3 mAb (Serotec) and flow cytometry
after incubation of T-cell clones (0.5 105; total volume, 0.2ml)
with Ag-presenting cells (0.25 105) and either PPD or PPD-
modified HSA.
Statistical analysis
The Mann–Whitney test was used for comparison of control and test
values.
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